Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin antagonists and heart failure.

David Hürlimann1, Frank Enseleit, Georg Noll

  • 1Cardio Vascular Center, Cardiology, University Hospital, CH - 8091 Zürich, Switzerland.

Current Hypertension Reports
|January 16, 2002
PubMed
Summary

New treatments targeting endothelin-1 (ET-1) show promise for chronic heart failure (CHF). Blocking ET-1 receptors improved hemodynamics and symptoms in CHF patients, offering potential for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular function in patients with advanced heart failure and continuous-flow or pulsatile ventricular assist devices.

Clinical research in cardiology : official journal of the German Cardiac Society·2024
Same author

Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.

European heart journal·2023
Same author

Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registry.

ESC heart failure·2022
Same author

How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry.

ESC heart failure·2022
Same author

Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2022
Same author

Endothelial SIRT6 deficiency promotes arterial thrombosis in mice.

Journal of molecular and cellular cardiology·2022

Area of Science:

  • Cardiology
  • Pharmacology
  • Translational Medicine

Background:

  • Chronic heart failure (CHF) involves impaired cardiac function and high mortality despite current treatments.
  • Elevated plasma endothelin-1 (ET-1) levels in CHF correlate with disease severity and predict mortality.
  • Novel therapeutic strategies are needed to address the persistent high mortality in CHF patients.

Purpose of the Study:

  • To evaluate the potential of endothelin receptor antagonists in managing chronic heart failure.
  • To assess the impact of ET-1 pathway inhibition on hemodynamic parameters and symptoms in CHF.

Main Methods:

  • Investigated combined ET(A/B) and selective ET(A) receptor antagonists in CHF patients.
  • Monitored hemodynamic improvements and symptom changes following antagonist administration.

Related Experiment Videos

Main Results:

  • Endothelin receptor antagonists demonstrated significant hemodynamic improvements in patients with CHF.
  • These agents showed potential in alleviating symptoms associated with chronic heart failure.

Conclusions:

  • Endothelin receptor antagonists represent a promising therapeutic approach for CHF.
  • Targeting the ET-1 pathway may improve hemodynamics, symptoms, and potentially the prognosis of patients with chronic heart failure.